Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pacira Pharmaceuticals has published the results from the first IMPROVE study in the online version of the Journal of Pain Research.
Subscribe to our email newsletter
The study compared the difference in opioid use, total hospital cost and length of stay (LOS) between patients receiving Exparel as the base of an opioid-sparing multimodal regimen in relation to a standard opioid-based postsurgical pain management regimen.
The IMPROVE study showed that the patients undergoing open colectomy in the standard opioid-based treatment arm and receiving an Exparel-based multimodal regimen had a 2.9-day reduction in median LOS, $3,084 reduction in mean total hospital cost and a 58 mg reduction in mean opioid consumption.
Pacira president and CEO Dave Stack said the study, which demonstrates a significant reduction in endpoints for both patient care and hospital economics, is now available in the public domain.
"Additional IMPROVE studies in laparoscopic colectomy and ileostomy reversal are nearing completion, and initial results seem to support what we have already seen in this IMPROVE study," Stack added.